Calculating The Impact Of Akebia Therapeutics Inc (AKBA)'s Pivotals
Akebia Therapeutics Inc (NASDAQ:AKBA) just gave word of the initiation of its pivotal trial in a second indication for its lead renal anemia candidate, Vadadustat.
August 12th, 2016 - News Stock Analysis
January 25th, 2016 - Hedge Funds News
January 20th, 2016 - Hedge Funds
November 29th, 2015 - Hedge Funds News
September 9th, 2015 - Hedge Funds Market Movers News
Returns since its inception in May 2014 (through May 20, 2024)